Hello!

We would like to welcome you to our EUMDS newsletter number 5. To subscribe/cancel to the EUMDS Registry Newsletter, please send a mail to: j.droste@hemat.umcn.nl with the word “Subscribe” or “Cancel” in the subject line.

Send Your Suggestions

Is there anything you’d like to see in the next newsletter? We’d like to hear from you! Please contact us if you have any suggestions, questions, or comments concerning any of the topics described in this Newsletter and on the Registry in general either by emailing Jackie Droste at j.droste@hemat.umcn.nl or calling at +31 24 3614794.

Inclusion

At the end of September 136 patients have been included in the registry, of whom one died. 42 different sites in 10 countries included at least 1 patient.

Database

A new release of the database is planned the 10th of October, which means that the website is unavailable this day. This new release will include warnings. There will be several kinds of warnings: for example laboratory results which are too low or too high will result in a warning. These warnings can be seen in the recruitment summary window and accessed by clicking on it. Subsequently the warning can be approved or cleared. Furthermore all warnings of a country will be send to the country coordinator by email. At the centre administration page, email addresses can be added or removed to whom these warnings should be sent.

Accrual

Overall accrual per month

Accrual per country

- Expected
- Actual
Drug related therapy
The Steering Committee will allow the use of hypomethylating agents (5-azacitidine and Decitabine) as single agents or in combination with histone deacetylase inhibitors and/or All trans retinoic acid (ATRA). Patients currently eligible for such therapy are likely to be only a small number, typically (but not exclusively) INT-1 with 5-10% blasts. Other active therapies such as erythropoietic stimulating agents, thalidomide, Antithymocyte globulin and lenalinomide are also allowed.

Meetings
The next Steering Committee meeting will be early February 2009 in Mannheim and a teleconference is scheduled the 17th of November 18.00-19.00 CET.
The next Operational Team meeting will also be early February 2009 in Mannheim. Teleconferences will be scheduled once the new database has gone live and is used for at least 2 weeks.

Screening log form
All clinical sites have to maintain an Investigator Site File, including the screening log form. Data for each patient that is screened and ay be entered into the study should be entered into the screening log form.

Organisation of United Kingdom
Lorna Barnard, ELN Registry Coordinator Clinical Trials
Department of Haematology
St James University Hospital
Leeds
UK

The EUMDS Registry involves 20 centres across the UK. It is coordinated centrally in Leeds but each centre has its own trial team including coordinators, research nurses, and principle investigators. In Leeds the team consists of Dr David Bowen (Principle Investigator), Dr Anne Critchley (Co investigator), Louise Arnold (Research Nurse) and Lorna Barnard (Registry Coordinator). Each centre is responsible for its own informed consent procedure and the data collection and entry onto the database with assistance if necessary from Leeds.
Once a centre has all the required approvals in place they have an initiation meeting and can then start recruiting patients. To date 6 centres in the UK are open to recruitment and a number of others will be shortly. Our first patient was registered in June and we have now just registered the 11th. Hopefully we are on track to recruit all 90 patients by the end of the enrolment period.
So far all centres in the UK are collecting the blood and urine samples for the registry. Some centres process and store these themselves, some process them and send them to Leeds for storage and the rest send them to Leeds for both processing and storage. All centres forward a copy of the sample record form via fax to the coordinators office in Leeds. I am responsible for the collection of the sample records forms for the whole project. Therefore I would be grateful if all centres storing samples would fax me a copy of the sample record form. We hope to perform global proteomic analysis of this large cohort of serum samples.

Sub study: Iron overload in MDS
A new dimension for the registry will be the planned sub studies. As written in newsletter 4, iron overload in MDS may be one of the new sub studies.
Iron accumulation is not only a result of iron overload due to transfusions, but also caused by increased intestinal iron absorption due to ineffective erythropoiesis. (See schematic picture presented for the iron sub study)
Iron accumulation in MDS patients due to stimulation of intestinal iron uptake by ineffective erythropoiesis

- Increased intestinal iron uptake
- Down-regulation of hepcidin
- High levels of GDF15

**Iron-related therapy**

- Bone marrow erythroblasts
- Ineffective erythropoiesis
- Circulating Haemoglobin

**Daily losses**

- ~ 1 mg
- Urine, faeces, nails, hair, skin
- Liver, other parenchymal organs, myoglobin in muscle

**Macrophages**

**Transferrin**

**Plasma**

**Daily losses**

**Menstrual or other blood loss**

GDF15 = growth differentiation factor 15.
